About 80% of 70 clinical isolates of Bacteroidesfragilis were inhibited by 4 ,ug of ciprofioxacin (Bay o 9867) per ml. The 90% MIC of ciprofloxacin was 8 jig/mI for other Bacteroides species, 2 ,ug/ml for Peptococcus species, 8 ,ig/ml for Peptostreptococcus species, and 16 ,ug/ml for Clostridium and Eubacterium species.
Ciprofioxacin (Bay o 9867), a new quinolone derivative, is chemically related to nalidixic acid. It was found to be effective against both gram-positive and gram-negative aerobic bacteria (4, 6 ) that were resistant to a variety of commonly used antimicrobial agents. In this study, we evaluated the in vitro activity of ciprofloxacin against anaerobic bacteria and compared its efficacy with that of cefoxitin and clindamycin, the antibiotics commonly used for the treatment of anaerobic infections.
The anaerobic bacteria used in this study were clinical isolates collected at Martin Luther King, Jr. General Hospital, Los Angeles, Calif. Identification of all isolates was confirmed before testing (3). The antimicrobial agents were obtained from the following sources: ciprofloxacin, Miles Laboratories, New Haven, Conn.; nalidixic acid, Winthrop Laboratories, New York, N.Y.; cefoxitin, Merck and Co., Inc., West Point, Pa.; and clindamycin, The Upjohn Co., Barceloneta, P.R. Stock solutions of each antimicrobial agent were prepared as recommended by the manufacturer.
MICs for ciprofloxacin were determined by the agar dilution method as previously described (5) . Bacteroides fragilis (ATCC 25285) and Clostridium perfringens (ATCC 13124) were used in each experiment as reference organisms with known MICs of the test antimicrobial agents. All cultures were incubated in the anaerobic glove box (1) for 48 h at 37°C. The MIC was defined as the lowest concentration of each antimicrobial agent that permitted no visible growth (5) .
In parallel experiments, 96 randomly selected strains were tested by the agar dilution method, processed in air, and incubated in anaerobic jars (GasPak; BBL Microbiology Systems, Cockeysville, Md.) and by the agar dilution method, processed, and incubated in an anaerobic chamber (Coy Laboratories, Irvine, Calif.). There was no significant difference between the MICs of ciprofloxacin derived from these two methods.
A total of 326 clinical isolates of anaerobic bacteria was tested for the activity of ciprofloxacin, nalidixic acid, cefoxitin, and clindamycin ( Table 1) . The results are presented as the MIC range, 50% MIC (MIC50), and MIC%0 of each antibiotic. Ciprofloxacin was effective against B. fragilis; nearly 80% of the strains were inhibited at 4 ,ug/ml, whereas strains of Bacteroides distasonis, Bacteroides vulgatus, and Bacteroides oralis showed MIC90s of .16 ,ug/ml. In contrast, strains of Bacteroides melaninogenicus were very * Corresponding author. ,ug/ml). The therapeutic effect of ciprofloxacin can be predicated upon the basis of total daily dosage required to achieve a serum level of 8 ,ug/ml or more to cover anaerobes, assuming that this dose can be safely given and well tolerated. Previously, in healthy human volunteers, a single peroral dose of 500 mg of ciprofloxacin produced a mean level in serum of 2.4 ,ug/ml at 1.25 h after administration (2) . We have found that in mice injected intraperitoneally with.a 40-or 80-mg/kg dose of ciprofloxacin a peak serum level of 8 or 28 ,ug/ml, respectively, was produced within 30 nin. At the end of 2 h the corresponding trough levels were 0.7 or 3 p.g/ml.
The observed efficacy of ciprofloxacin against anaerobic bacteria in our study, together with published data on its effect on aerobic bacteria (4, 6) , encourages the evaluation of this novel quinolone in the treatment of mixed anaerobic infections in humans.
